Protagenic Therapeutics, Incnew 8-K filings

Protagenic Therapeutics, Inc. has terminated its acquisition of Phytanix Bio and settled related litigation, paying $310,000 in the process.

Protagenic Therapeutics, Inc. announced its common stock and warrants will be delisted from Nasdaq and begin trading on the over-the-counter market due to non-compliance with listing rules.

Protagenic Therapeutics received a Nasdaq delisting notice due to insufficient stockholders' equity and delayed financial reporting.

Jennifer Chao has resigned from the Board of Directors of Protagenic Therapeutics, Inc., effective November 3, 2025, with no reported disagreements.

Protagenic Therapeutics, Inc. has filed a lawsuit in Delaware Chancery Court seeking to rescind its acquisition of Phytanix Bio, Inc. or obtain damages.

Protagenic Therapeutics, Inc. filed an amendment to its Form 8-K/A to update the auditor's consent related to the Phytanix Bio acquisition.

Protagenic Therapeutics acquires Phytanix Bio, expanding its drug pipeline and transitioning to a virtual operating model.

Protagenic Therapeutics received a Nasdaq non-compliance notice for its delayed Q2 2025 filing and changed auditors, while also announcing progress in its PT00114 Phase I clinical trial.

Protagenic Therapeutics, Inc. announced a significant restructuring plan, including executive terminations and a shift to a virtual operating model, to focus on its lead clinical program.

Protagenic Therapeutics, Inc. announced the grant of a new patent in Japan for its modified stilbenoid program drug candidates, providing exclusivity for compounds and their medical use in treating epilepsy and seizures.

Protagenic Therapeutics, Inc. announced the unanimous appointment of Timothy R. Wright as an independent Class II director to its Board of Directors, effective July 18, 2025.

Protagenic Therapeutics, Inc. has declared a distribution of rights to its stockholders, allowing them to purchase additional common stock at $0.01 per share, aimed at preserving the relative ownership stakes after its acquisition of Phytanix Bio.

Protagenic Therapeutics announces the receipt of $3.1 million from warrant exchanges and exercises, intended to bolster working capital and advance drug development programs.

Protagenic Therapeutics enters into an agreement to exchange 459,420 warrants for 367,544 shares of common stock with an unaffiliated third-party investor.

Protagenic Therapeutics and Phytanix Bio combine in an all-stock transaction, forming Phytanix, Inc., a neuroactive biopharmaceutical company with a diverse pipeline.

Protagenic Therapeutics enacted a 1-for-14 reverse stock split, effective May 5, 2025, to comply with Nasdaq's minimum bid price requirement.

Protagenic Therapeutics' Board of Directors has approved a 1-for-14 reverse stock split, effective May 5, 2025, to meet Nasdaq's minimum bid price requirement.

Protagenic Therapeutics stockholders approved a proposal granting the Board of Directors discretionary authority to implement a reverse stock split at a ratio between 1-for-10 and 1-for-20.

Protagenic Therapeutics' stockholders approved the repricing of outstanding stock options, and the Board subsequently repriced the options to $0.2655 per share.

Protagenic Therapeutics held its annual meeting on February 21, 2025, electing directors and approving proposals related to stock options, warrant shares, and the equity incentive plan.

Protagenic Therapeutics received a delisting notice from Nasdaq after failing to meet the minimum bid price requirement, but the company's securities remain listed pending a hearing.

Protagenic Therapeutics receives a notification from Nasdaq regarding non-compliance with listing rules due to a delay in holding its annual shareholder meeting.

Protagenic Therapeutics amends its sales agreement with B. Riley Securities to facilitate a potential $1.2 million at-the-market offering of common stock.

Protagenic Therapeutics is appealing a Nasdaq delisting notice after failing to meet minimum stockholders' equity requirements, with a hearing scheduled for January 30, 2025.

Protagenic Therapeutics has received a delisting notice from Nasdaq after failing to meet the minimum stockholders' equity requirement, with trading potentially suspended on November 29, 2024.

Protagenic Therapeutics successfully closed a private placement, raising approximately $1.275 million in gross proceeds.

Protagenic Therapeutics has announced a private placement to raise $1.275 million through the sale of common stock and warrants.

Protagenic Therapeutics has announced updated timelines for the clinical development of its drug candidate, PT00114, including the start of a Phase I multiple dose study and a Phase IIa study.

Protagenic Therapeutics has received a notice from Nasdaq for failing to maintain the minimum bid price of $1.00 per share, placing its listing at risk.

Protagenic Therapeutics has received a notice from Nasdaq for failing to meet the minimum stockholders' equity requirement for continued listing.